ReviewLab on a chip2023
Integrated "lab-on-a-chip" microfluidic systems for isolation, enrichment, and analysis of cancer biomarkers.
Review in Lab on a chip, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- In Situ Fabrication of Complex Hollow Nickel Microstructures via Filament-Guided Electrolyte-Column Electrodeposition.Micromachines · 2026Article
- Smart responsive hydrogels combined with AI design for tumor therapy.Acta pharmaceutica Sinica. B · 2026Review
- A Spore-Based Biosensor-on-Pillar Platform for Detecting ß-Lactam Antibiotics in Milk.Molecules (Basel, Switzerland) · 2026Article
- Cascading inertial microfluidics for high-throughput, multi-scale enrichment of tumor cells and intact clusters towards enhanced malignancy diagnosis.Microsystems & nanoengineering · 2026Article
- Trends in Vibrational Spectroscopy: NIRS and Raman Techniques for Health and Food Safety Control.Sensors (Basel, Switzerland) · 2026Review
- Magnetic Nanoparticle-Integrated Microfluidic Chip Enables Reliable Isolation of Plasma Cell-Free DNA for Molecular Diagnostics.Diagnostics (Basel, Switzerland) · 2026Article
- From microfluidics to nanodelivery: artificial intelligence reshapes neuropharmacology research strategies.Frontiers in pharmacology · 2026Review
- A proposal of good manufacturing practices (GMP) laboratory for CAR T-cell therapy in Latin America and the Caribbean: challenges and opportunities.Frontiers in public health · 2026Review
- Nanodevice Approaches for Detecting Micro- and Nanoplastics in Complex Matrices.Nanomaterials (Basel, Switzerland) · 2025Review
- Microfluidic platform for understanding Parkinson's disease and α-synuclein conformation.Translational neurodegeneration · 2025Review
- Integrated microfluidic platforms for extracellular vesicles: Separation, detection, and clinical translation.APL bioengineering · 2025Review
- From lab to life: technological innovations in transforming cancer metastasis detection and therapy.Discover oncology · 2025Review
- High-Viability Circulating Tumor Cells Sorting From Whole Blood at Single Cell Level Using Laser-Induced Forward Transfer-Assisted Microfiltration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Review
- Construction of Multiplexed Assays on Single Anisotropic Particles Using Microfluidics.ACS central science · 2025Article
- Exosomes: innovative biomarkers leading the charge in non-invasive cancer diagnostics.Theranostics · 2025Review
- Bevacizumab and anlotinib combination therapy acts via HIF-1α suppression to exert synergistic anti-angiogenic and anti-tumor effects in non-small cell lung cancer.Frontiers in immunology · 2025Article
- Recent advances in aptamer-based biosensing technology for isolation and detection of extracellular vesicles.Frontiers in cell and developmental biology · 2025Review
- Advancing clinical biochemistry: addressing gaps and driving future innovations.Frontiers in medicine · 2025Review
- Current biological implications and clinical relevance of metastatic circulating tumor cells.Clinical and experimental medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The liquid biopsy has garnered considerable attention as a complementary clinical tool for the early detection, molecular characterization and monitoring of cancer over the past decade. In contrast to traditional solid biopsy techniques, liquid biopsy offers a less invasive and safer alternative for routine cancer screening. Recent advances in microfluidic technologies have enabled handling of liquid biopsy-derived biomarkers with high sensitivity, throughput, and convenience. The integration of these multi-functional microfluidic technologies into a 'lab-on-a-chip' offers a powerful solution for processing and analyzing samples on a single platform, thereby reducing the complexity, bio-analyte loss and cross-contamination associated with multiple handling and transfer steps in more conventional benchtop workflows. This review critically addresses recent developments in integrated microfluidic technologies for cancer detection, highlighting isolation, enrichment, and analysis strategies for three important sub-types of cancer biomarkers: circulating tumor cells, circulating tumor DNA and exosomes. We first discuss the unique characteristics and advantages of the various lab-on-a-chip technologies developed to operate on each biomarker subtype. This is then followed by a discussion on the challenges and opportunities in the field of integrated systems for cancer detection. Ultimately, integrated microfluidic platforms form the core of a new class of point-of-care diagnostic tools by virtue of their ease-of-operation, portability and high sensitivity. Widespread availability of such tools could potentially result in more frequent and convenient screening for early signs of cancer at clinical labs or primary care offices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.